43 results
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
13 Feb 24
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update
7:34pm
will soon be available on the National Institutes of Health (“NIH”) clinicaltrials.gov website and the European Union Clinical Trials Register website
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
16 Jan 24
InMed Pharmaceuticals Provides Business Update and Milestones for 2024
2:12pm
”) clinicaltrials.gov website and the European Union Clinical Trials Register website. Additionally, an abstract will soon be published in Itch, the official
8-K
EX-10.1
INM
InMed Pharmaceuticals Inc
27 Oct 23
Entry into a Material Definitive Agreement
7:16pm
’ employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary, and neither the Company nor any
8-K
EX-10.1
INM
InMed Pharmaceuticals Inc
21 Nov 22
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
7:02pm
Subsidiaries’ employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary, and neither
8-K
EX-10.1
zv3pp c0sy4ae
13 Sep 22
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
9:59pm
424B3
hl1mgrviv1l
6 Jul 22
Prospectus supplement
2:43pm
8-K
EX-10.1
lg8i45a6tv3b gz
3 Jun 22
Entry into a Material Definitive Agreement
9:51pm
8-K
EX-10.2
tpw0fv0
3 Jun 22
Entry into a Material Definitive Agreement
9:51pm
424B5
dyaghdag3922t
3 Jun 22
Prospectus supplement for primary offering
9:45pm
424B3
nlayj8q58duvs4vxubw6
25 Apr 22
Prospectus supplement
5:02pm
8-K
EX-10.1
67yga3
7 Apr 22
Entry into a Material Definitive Agreement
4:47pm
424B3
gyvxxqeu
7 Apr 22
Prospectus supplement
4:46pm
S-3
2flat3e
4 Feb 22
Shelf registration
4:36pm
8-K
EX-2.1
viiz8t12 slu
13 Oct 21
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids
5:00pm